Format

Send to

Choose Destination
Cancer Invest. 2004;22(2):304-11.

Development of the proteasome inhibitor Velcade (Bortezomib).

Author information

1
Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA. julian.adams@ipi.com

Abstract

The dipeptide boronic acid analogue VELCADE (Bortezomib; formerly known as PS-341, LDP-341 and MLM341) is a potent and selective inhibitor of the proteasome, a multicatalytic enzyme that mediates many cellular regulatory signals by degrading regulatory proteins or their inhibitors. The proteasome is, thus, a potential target for pharmacological agents. Bortezomib, the first proteasome inhibitor to reach clinical trials, has shown in vitro and in vivo activity against a variety of malignancies, including myeloma, chronic lymphocytic leukemia, prostate cancer, pancreatic cancer, and colon cancer. The drug is rapidly cleared from the vascular compartment, but a novel pharmacodynamic assay has shown that bortezomib--mediated proteasome blockade is dose-dependent and reversible. Based on phase I studies demonstrating that bortezomib has manageable toxicities in patients with advanced cancers, phase II trials have been initiated for both solid and hematological malignancies.

PMID:
15199612
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center